Post date
29/11/2022
Every day in Belgium, 59 individuals are victims of a stroke[1]. The first cause of all deaths, cardiovascular diseases could be avoided in 80% of cases.
The biotech company, SPINOVIT, has developed
Post date
03/11/2022
Funding will support development of next generation orthopedic products that provide accelerated healing through single treatment cures
Mont Saint-Guibert, Belgium – November 3, 2022 – Novadip
Post date
04/10/2022
Botalys aims to become the world leader in hydroponic precision farming of medicinal plants thanks to its revolutionary technological platform.
Belgian company Botalys, a world pioneer in the
Post date
29/06/2022
A major turning point for people at risk of cardiovascular disease, obesity and diabetes.
Mont-Saint-Guibert, June 29, 2022
- A crucial step has been taken by the Belgian company The Akkermansia
Post date
16/06/2022
LEUVEN, Belgium, June 16th, 2022 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce that
Post date
02/03/2022
Louvain-la-Neuve, March 1, 2022 – VIVES today announced that AbbVie (NYSE: ABBV) has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio
Post date
14/12/2021
Sunrise, a healthtech company founded in 2015 in Belgium, has just closed a €3.25 million fundraising round. Led by Kurma Partners, this round of financing, in which the Vives-IUF fund linked to
Post date
28/10/2021
Mont Saint-Guibert, Belgium – October 28, 2021 – Novadip Biosciences, a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs
Post date
22/10/2021
Louvain-la-Neuve, 22 October 2021 – VOCSens raises €2.5 million in seed funding in order to industrialise its gas microsensors. The objective? The aim is to commercialise its micro gas sensors in the
Post date
09/09/2021
Belgian biotechnology company ViroVet partnered with researchers at The Pirbright Institute in 2019 to develop and test the first antiviral drugs that act against African swine fever (ASF). In the
Post date
01/09/2021
European first in next-generation bacterium: pasteurized Akkermansia muciniphila from A-Mansia Biotech receives the green light from EFSA's scientific committee.
Excellent news for people at risk of
Post date
30/06/2021
This new fundraising secures the financing of its Phase IIB study for HepaStem® in its flagship indication, Acute on Chronic Liver Failure (ACLF), a severe liver disease affecting more than 50000